Literature DB >> 19298607

Influence of Enterococcus faecium SF68 probiotic on giardiasis in dogs.

K W Simpson1, M Rishniw, M Bellosa, J Liotta, A Lucio, M Baumgart, G Czarnecki-Maulden, J Benyacoub, D Bowman.   

Abstract

BACKGROUND: Giardiasis is a common, potentially zoonotic disease, and dogs often harbor and shed cysts without showing clinical signs. Treatment with the probiotic Enterococcus faecium SF68 has been shown to stimulate mucosal and systemic immunity in a variety of animal models and in young dogs, and to reduce giardial cyst and antigen shedding in rodents. HYPOTHESIS: Adult dogs with chronic naturally acquired giardiasis will have decreased giardial fecal cyst and antigen shedding and increased innate and adaptive immunity after 6 weeks probiotic treatment with E. faecium SF68. ANIMALS: Twenty adult dogs.
METHODS: After a 6-week dietary equilibration period, dogs were randomized to receive E. faecium SF68 or placebo for 6 weeks, and then crossed over to the alternate treatment. We measured cyst shedding, fecal giardial antigen, fecal immunoglobulin A (IgA) concentration, and circulating leukocyte phagocytic activity at multiple timepoints to determine the effect of E. faecium SF68 on giardiasis and immune responses in these dogs.
RESULTS: No differences were observed between placebo or E. faecium SF68 treatment for giardial cyst shedding, fecal antigen shedding, fecal IgA concentration, or leukocyte phagocytic activity.
CONCLUSIONS: Short-term treatment with E. faecium SF68 of dogs with chronic naturally acquired subclinical giardiasis fails to affect giardial cyst shedding or antigen content and does not alter innate or adaptive immune responses.

Entities:  

Mesh:

Year:  2009        PMID: 19298607     DOI: 10.1111/j.1939-1676.2009.0283.x

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  9 in total

1.  Effect of native Lactobacillus murinus LbP2 administration on total fecal IgA in healthy dogs.

Authors:  Luis Delucchi; Martín Fraga; Karen Perelmuter; Claudia Della Cella; Pablo Zunino
Journal:  Can J Vet Res       Date:  2014-04       Impact factor: 1.310

2.  Randomized, controlled trial evaluating the effect of multi-strain probiotic on the mucosal microbiota in canine idiopathic inflammatory bowel disease.

Authors:  Robin White; Todd Atherly; Blake Guard; Giacomo Rossi; Chong Wang; Curtis Mosher; Craig Webb; Steve Hill; Mark Ackermann; Peter Sciabarra; Karin Allenspach; Jan Suchodolski; Albert E Jergens
Journal:  Gut Microbes       Date:  2017-07-05

Review 3.  Understanding the canine intestinal microbiota and its modification by pro-, pre- and synbiotics - what is the evidence?

Authors:  Silke Schmitz; Jan Suchodolski
Journal:  Vet Med Sci       Date:  2016-01-11

4.  The influence of probiotic bacteria and human gut microorganisms causing opportunistic infections on Blastocystis ST3.

Authors:  M Lepczyńska; E Dzika
Journal:  Gut Pathog       Date:  2019-02-14       Impact factor: 4.181

5.  Efficacy of an orally administered anti-diarrheal probiotic paste (Pro-Kolin Advanced) in dogs with acute diarrhea: A randomized, placebo-controlled, double-blinded clinical study.

Authors:  Sophie L Nixon; Lindsay Rose; Annika T Muller
Journal:  J Vet Intern Med       Date:  2019-03-18       Impact factor: 3.333

6.  Clinical effect of probiotics in prevention or treatment of gastrointestinal disease in dogs: A systematic review.

Authors:  Anders P Jensen; Charlotte R Bjørnvad
Journal:  J Vet Intern Med       Date:  2019-07-16       Impact factor: 3.333

Review 7.  Microbiota and probiotics in canine and feline welfare.

Authors:  Łukasz Grześkowiak; Akihito Endo; Shea Beasley; Seppo Salminen
Journal:  Anaerobe       Date:  2015-04-08       Impact factor: 3.331

Review 8.  Canine chronic enteropathy-Current state-of-the-art and emerging concepts.

Authors:  Albert E Jergens; Romy M Heilmann
Journal:  Front Vet Sci       Date:  2022-09-21

Review 9.  Probiotics in the management of Giardia duodenalis: an update on potential mechanisms and outcomes.

Authors:  Nasrin Dashti; Mitra Zarebavani
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-07-29       Impact factor: 3.000

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.